Eli Lilly is betting big on its experimental oral weight-loss drug even before reporting data from its late-stage trial by ...
JPMorgan is sticking with Eli Lilly (LLY) as its top biopharma pick for 2025, while also highlighting Gilead Sciences (GILD) ...